<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227251</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-009</org_study_id>
    <secondary_id>2014-001977-15</secondary_id>
    <nct_id>NCT02227251</nct_id>
  </id_info>
  <brief_title>Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with&#xD;
      relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic&#xD;
      options of demonstrated clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, Phase 2b study of the selective inhibitor of nuclear&#xD;
      export (SINE) selinexor (40 or 60 milligrams [mg]) given orally (PO) to participants with R/R&#xD;
      DLBCL). The study is being conducted in 2 parts (Part 1 and Part 2). For Part 1, a fixed 60&#xD;
      mg dose of selinexor is given orally to 130 participants with R/R DLBCL who have no&#xD;
      therapeutic options of demonstrated clinical benefit and who meet eligibility criteria and&#xD;
      have none of the exclusion criteria will be enrolled to receive selinexor until either&#xD;
      disease progression or intolerance has occurred. For Part 2, approximately 110 participants&#xD;
      (55 in each arm) are planned to be enrolled. Participants will be randomized (open label) in&#xD;
      a 1:1 ratio to either Arm A (40 mg) or Arm B (60 mg) and will be stratified based on history&#xD;
      of prior autologous stem cell transplantation (ASCT) versus no prior ASCT. All the&#xD;
      participants will be followed until disease progression and/or death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Overall Response Rate (ORR)</measure>
    <time_frame>One year</time_frame>
    <description>Assessed according to the revised response criteria based on the Guidelines of the International Working Group (IWG).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Response Rate (ORR) Based on Lugano Criteria</measure>
    <time_frame>From initial randomization until date of disease progression or death (maximum of 1 year from Part 2 randomization)</time_frame>
    <description>Assessed according to the response assessment of lymphoma based on Lugano classification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Duration of Response (DOR)</measure>
    <time_frame>From time of first response until disease progression or death (maximum of 1 year from Part 1 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Disease Control Rate (DCR)</measure>
    <time_frame>From initial response until disease progression or death (maximum of 1 year from Part 1 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Baseline up to 30 days after last dose (maximum of 1 year from Part 1 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>From Baseline up to 30 days after last dose (maximum of 1 year from Part 1 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of response (DOR)</measure>
    <time_frame>From time of first response (Part 2) until disease progression or death (maximum of 1 year from Part 2 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Disease control rate (DCR)</measure>
    <time_frame>From initial response (Part 2) until disease progression or death (maximum of 1 year from Part 2 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall Response Rate (ORR) Based on Modified Lugano Criteria</measure>
    <time_frame>From initial randomization until date of disease progression or death (maximum of 1 year from Part 2 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants with Treatment-emergent Adverse Events</measure>
    <time_frame>From Baseline up to 30 days after last dose (maximum of 1 year from Part 2 randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>From Baseline up to 30 days after last dose (maximum of 1 year from Part 2 randomization)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: Selinexor 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received fixed dose of 60 mg selinexor orally, twice weekly (BIW) on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1-4 of each four week (each cycle of 28 days) cycle (total of 8 doses per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm A-Selinexor 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received selinexor 40 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles (28 days) until disease progression (total of 8 doses per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm B-Selinexor 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received selinexor 60 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles) for 2 cycles (each cycle of 28 days) followed by 60 mg once weekly (QW) in the subsequent cycles until disease progression (total of 8 doses per cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral</description>
    <arm_group_label>Part 1: Selinexor 60 mg</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral</description>
    <arm_group_label>Part 2: Arm A-Selinexor 40 mg</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral</description>
    <arm_group_label>Part 2: Arm B-Selinexor 60 mg</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Parts 1 and 2):&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines. The participant must provide informed consent prior to the first screening&#xD;
             procedure.&#xD;
&#xD;
          -  Age greater than or equal to (≥) 18 years.&#xD;
&#xD;
          -  ECOG performance status of less than or equal to (≤) 2.&#xD;
&#xD;
          -  Participants should have estimated life expectancy of greater than (&gt;) 3 months at&#xD;
             study entry.&#xD;
&#xD;
          -  Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from&#xD;
             previously diagnosed indolent lymphoma (e.g., follicular lymphoma).&#xD;
&#xD;
          -  Participants must have received at least 2 but no more than 5 previous systemic&#xD;
             regimens for the treatment of their de novo or transformed DLBCL including (i) at&#xD;
             least 1 course of anthracycline-based chemotherapy (unless absolutely contraindicated&#xD;
             due to cardiac dysfunction, in which case other active agents such as etoposide,&#xD;
             bendamustine, or gemcitabine must have been given) and (ii) at least 1 course of&#xD;
             anti-CD20 immunotherapy (e.g., rituximab), unless contraindicated due to severe&#xD;
             toxicity. Participants who were considered ineligible for standard multi-agent&#xD;
             immunochemotherapy must have received at least 2 and no more than 5 prior treatment&#xD;
             regimens including at least 1 course of anti-CD20 antibodies and must be approved by&#xD;
             the Medical Monitor. Prior stem cell transplantation is allowed; induction,&#xD;
             consolidation, stem cell collection, preparative regimen and transplantation ±&#xD;
             maintenance are considered a single line of therapy.&#xD;
&#xD;
          -  Female participants of child-bearing potential must have a negative serum pregnancy&#xD;
             test at screening and agree to use reliable methods of contraception for 3 months&#xD;
             after their last dose of medication. Male participants must use a reliable method of&#xD;
             contraception if sexually active with a female of child-bearing potential. For both&#xD;
             male and female participants, effective methods of contraception must be used&#xD;
             throughout the study and for 3 months following the last dose.&#xD;
&#xD;
        Part 1 additional inclusion criteria:&#xD;
&#xD;
          -  For participants whose most recent systemic anti-DLBCL therapy induced a PR or CR, at&#xD;
             least 60 days must have elapsed since the end of that therapy. For all other&#xD;
             participants, at least 14 weeks (98 days) must have elapsed since the end of their&#xD;
             most recent systemic anti-DLBCL therapy. . Palliative localized radiation within the&#xD;
             therapy-free interval is allowed. Non-chemotherapy maintenance will not be considered&#xD;
             anti DLBCL therapy, and therefore is allowed during the therapy-free interval.&#xD;
&#xD;
          -  Documented clinical or radiographic evidence of progressive DLBCL prior to dosing.&#xD;
&#xD;
          -  Participants must have measurable disease per the revised criteria for response&#xD;
             assessment of lymphoma. Lymph nodes should be considered abnormal if the long axis is&#xD;
             &gt;1.5 centimeter (cm), regardless of the short axis. If a lymph node has a long axis of&#xD;
             1.1 to 1.5 cm, it should only be considered abnormal if its short axis is &gt;1.0. Lymph&#xD;
             nodes ≤1.0 by ≤1.0 will not be considered abnormal for relapse or PD.&#xD;
&#xD;
        Part 2 additional inclusion criteria:&#xD;
&#xD;
        • At least 3 weeks (21 days) must have elapsed since the end of participant's most recent&#xD;
        systemic anti-DLBCL therapy (prior to Cycle 1 Day 1). Palliative localized radiation within&#xD;
        the therapy-free interval is allowed.Non-chemotherapy maintenance will not be considered&#xD;
        anti-DLBCL therapy, and therefore is allowed during the therapy-free interval.&#xD;
&#xD;
        • Adequate hematopoietic function: (i) Hemoglobin ≥10.0 grams per deciliters (g/dL) within&#xD;
        14 days of starting therapy (participant may receive red blood cell [RBC] transfusion&#xD;
        within 14 days).&#xD;
&#xD;
        (ii) Absolute neutrophil count ≥1000 cells/millimeter (mm^3) (use of granulocyte growth&#xD;
        factors prior to and during the study is acceptable).&#xD;
&#xD;
        (iii) Platelet count ≥100,000/mm^3 within 14 days of starting therapy (use of platelet&#xD;
        growth factors prior to and during the study is acceptable).&#xD;
&#xD;
          -  Participants must have measurable disease per the revised criteria for response&#xD;
             assessment of lymphoma. Lymph nodes should be considered abnormal if the long axis is&#xD;
             &gt;1.5 cm, regardless of the short axis. Extranodal lesion should be considered abnormal&#xD;
             if the long axis is &gt;1.0 cm.&#xD;
&#xD;
        Exclusion Criteria (Parts 1 and 2):&#xD;
&#xD;
          -  Participants who are pregnant or lactating.&#xD;
&#xD;
          -  Primary mediastinal (thymic) large B-cell lymphoma (PMBL)&#xD;
&#xD;
          -  Participants must not be eligible for high-dose chemotherapy with autologous stem cell&#xD;
             transplantation rescue (Investigator must provide detailed documentation for&#xD;
             ineligibility).&#xD;
&#xD;
          -  Participants who have not recovered to Grade ≤1 clinically significant adverse events,&#xD;
             or to their baseline, from their most recent systemic anti-DLBCL therapy.&#xD;
&#xD;
          -  Major surgery within 2 weeks of first dose of study treatment.&#xD;
&#xD;
          -  Participants with active hepatitis B virus (HBV), hepatitis C virus (HCV), or human&#xD;
             immunodeficiency virus (HIV) infections.&#xD;
&#xD;
          -  Psychiatric illness or substance use that would prevent the participant from giving&#xD;
             informed consent or being compliant with the study procedures.&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
             (i) A circulating lymphocyte count of &gt;50,000/L. (ii) Hepatic dysfunction: bilirubin&#xD;
             &gt;2.0 times the upper limit of normal (ULN) (except participants with Gilbert's&#xD;
             syndrome: total bilirubin of &gt;3*ULN) and alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) &gt;2.5 times ULN. In participants with known liver involvement of&#xD;
             their DLBCL, AST and ALT &gt;5*ULN.&#xD;
&#xD;
        (iii) Severe renal dysfunction: estimated creatinine clearance of &lt;30 mL/min, measured in&#xD;
        24-hour urine or calculated using the formula of Cockroft and Gault [(140-Age)*Mass&#xD;
        (kg)/(72*creatinine mg/dL); multiply by 0.85 if female].&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the Investigator's opinion, could compromise the participant's safety.&#xD;
&#xD;
          -  Participants with active graft-versus-host disease after allogeneic stem cell&#xD;
             transplantation. At least 4 months must have elapsed since completion of allogeneic&#xD;
             stem cell transplantation.&#xD;
&#xD;
          -  Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics,&#xD;
             antivirals, or antifungals on Cycle 1 Day 1; however, prophylactic use of these agents&#xD;
             is acceptable even if parenteral.&#xD;
&#xD;
          -  Participants unable to swallow tablets, participants with malabsorption syndrome, or&#xD;
             any other gastrointestinal disease or gastrointestinal dysfunction that could&#xD;
             interfere with absorption of study treatment.&#xD;
&#xD;
        Part 1 additional exclusion criteria:&#xD;
&#xD;
          -  For participants whose most recent systemic anti-DLBCL therapy induced a PR or CR:&#xD;
             Radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer&#xD;
             therapy other than glucocorticoids &lt;60 days or &lt;14 weeks prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Known central nervous system lymphoma or meningeal involvement.&#xD;
&#xD;
          -  DLBCL with mucosa-associated lymphoid tissue [MALT] lymphoma, composite lymphoma&#xD;
             (Hodgkin's lymphoma+NHL), or DLBCL transformed from diseases other than indolent NHL.&#xD;
&#xD;
          -  Unstable cardiovascular function:&#xD;
&#xD;
             (i) Symptomatic ischemia, or (ii) Uncontrolled clinically significant conduction&#xD;
             abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st&#xD;
             degree atrioventricular block or asymptomatic left anterior fascicular block /right&#xD;
             bundle branch block will not be excluded), or (iii) Congestive heart failure of New&#xD;
             York Heart Association Class ≥3, or (iv) Myocardial infarction within 3 months.&#xD;
&#xD;
          -  Participants with a BSA &lt;1.4 m^2 as calculated per Dubois 1916 or Mosteller 1987.&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
             (i) Absolute neutrophil count (ANC) &lt;1000 cells/mm^3 or platelet count &lt;75,000/mm^3&#xD;
             during screening and on Cycle 1 Day 1. Use of granulocyte-stimulating factors and&#xD;
             platelet growth factors prior to and during the study is acceptable.&#xD;
&#xD;
        (ii) Hematopoietic dysfunction: hemoglobin &lt; 10.0 g/dL within 14 days of and including&#xD;
        Cycle 1 Day 1 and/or patients receiving red blood cell (RBC) transfusion within 14 days of&#xD;
        and including Cycle 1 Day 1.&#xD;
&#xD;
          -  Participants who have been committed to an institution by official or judicial order.&#xD;
&#xD;
          -  Participants with dependency on the Sponsor, Investigator or study site.&#xD;
&#xD;
        Part 2 additional exclusion criteria:&#xD;
&#xD;
          -  Participants with active HBV, HVC, or HIV infections. Participants with active HBV are&#xD;
             allowed if antiviral therapy for hepatitis B has been given for &gt;8 weeks and viral&#xD;
             load is &lt;100 International units per milliliters (IU/mL) prior to first dose of study&#xD;
             treatment. Participants with known history of HCV or found to be HCV antibody positive&#xD;
             on screening, are allowed if there is documentation of negative viral load per&#xD;
             institutional standard. Participants with HIV who have CD4+T-cell counts ≥350&#xD;
             cells/microliter (mcL), negative viral load per institutional standard, and no history&#xD;
             of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections in the&#xD;
             last year are allowed.&#xD;
&#xD;
          -  Known active central nervous system lymphoma or meningeal involvement. Participants&#xD;
             with a history of CNS disease treated into remission may be enrolled.&#xD;
&#xD;
          -  DLBCL with MALT lymphoma, composite lymphoma (Hodgkin's lymphoma + NHL), DLBCL arising&#xD;
             from CLL (Richter's transformation), or high-grade B-cell lymphoma.&#xD;
&#xD;
          -  Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to Day 1 dosing or&#xD;
             strong CYP3A inducers ≤14 days prior to Day 1 dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UACC Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Boca Raton Cancer Research Medical Center</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center/Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/ Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Hospital &amp; Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital, Ingham Institute of Medical Research</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle Hospital</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Epworth Hospital</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3001</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck für Innere Medizin</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>LKH Leoben Department for Haemato-Oncology</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akh Linz Innere Med III - Zentrum für Hämatologie und med. Onkologie</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Uni. Klinik für Innere Medizin III Universitätsklinikum der PMU LKH Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna (MUW) Department of Medicine I</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Univ. General Hospital Hietzing</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CH Jolimont</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>H-Hartziekenhuis Roeselare-Menen</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital for Active Treatment Dr. Georgi Stranski</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Haematological Diseases EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B Davis Jewish General Hospital/McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Lyon</state>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Unite Hemopathies Lymphoides Chu Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Chu Dijon-Bourgogne - Hematologie Clinique</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hospitalier de la Rochelle-Ré-Aunis</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude-Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hostpial Saint Louis - CIRCO (Centre d'Investigations et de Recherche Clinique en Oncologie)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Service d'Hématologie Adult</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin (Benjamin Franklin Campus)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin (Virchow Campus)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ev. Diakonie-Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Haematologie and Onkologie-Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-University Halle-Wittenberg Department of Oncology</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg Medizinische Klinik V Hämatologie, Onkologie und Rheumatologie</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten Klinik für Innere Medizin III - Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum München</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Haematology Department and HCT Unit G.Papanicolaou Hospital</name>
      <address>
        <city>Exochi</city>
        <state>Thessaloniki</state>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niki Stavroyianni</last_name>
      <phone>+302313307533</phone>
      <email>niki.stavroyianni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Niki Stavroyianni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Clinic,General Hospital of Athens,G. Gennimatos</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theodoros Marinakis</last_name>
      <phone>00306932704780</phone>
      <email>tpmarin1@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Theodoros Marinakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National &amp; Kapodistrian University of Athens, Laiko General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hematology Department Laiko General Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theodoros Vassilakopoulos</last_name>
      <phone>+30 6945472338</phone>
      <email>theopvass@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Theodoros Vassilakopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Depth of Internal Medicine, Attiko University Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TSIRIGOTIS PANAGIOTIS</last_name>
      <phone>+306944618814</phone>
      <email>panagtsirigotis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>TSIRIGOTIS PANAGIOTIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National &amp; Kapodistrian University of Athens, Attiko University Hospital</name>
      <address>
        <city>Chaidari</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Department of clinical hematology ,university hospital Ioannina</name>
      <address>
        <city>Ioánnina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eleni Kapsali</last_name>
      <phone>0032651099650</phone>
      <email>elkapsali@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eleni Kapsali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Patras Medical School</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Általános Orvosi Kar</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet &quot;A&quot; Belgyógyászati Onkológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Department of Medicine and Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>DEKK Belgyogyaszati Klinika Hematologia</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem, ÁOK, I. számú Belgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Veszprém Megyei Csolnoky Ferenc Kórház</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CSolnoky ferenc Hospital</name>
      <address>
        <city>Veszprém</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre, IGIMS</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>800014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SRM Institutes for Medical Science</name>
      <address>
        <city>Vadapalani</city>
        <state>Chennai</state>
        <zip>600026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Thiruvananthapuram</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Prince Aly Khan Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital and Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Sciences &amp; SUM Hospital</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College and Hospital</name>
      <address>
        <city>Ludhiāna</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cancer Institute (WIA)</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Saveetha Medical College Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>602105</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>G. Kuppu Swamy Naidu Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641037</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital &amp; Research Centre</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>King George's Medical University (KGMU)</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nil Ratan Sircar Medical College and Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Netaji Subhas Chandra Bose Cancer Research Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700094</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>TATA Memorial Centre</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700156</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Netaji Subhas Chandra Bose Cancer Research Institute</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>70016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IRCH, All India Institute of Medical Sciences</name>
      <address>
        <city>Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dr. B.R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hematology-Soroka</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rambam Healthcare Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wolfson MC</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>69710</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>TLV Sorasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto di Ematologia Seragnoli Pad 8 Universita di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SODc Ematologica ,AOU Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Nassi</last_name>
      <phone>00390557947358</phone>
      <email>nassil@aou-careggi.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Luca Nassi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità SCDU Ematologia</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
      <phone>003903213732094</phone>
      <email>gianluca.gaidano@med.uniupo.it</email>
    </contact>
    <investigator>
      <last_name>Riccardo Bruna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology &amp; Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pinto</last_name>
      <phone>+39 (0) 81 5903 1816</phone>
      <email>a.pinto@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Pinto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia, Division of Hematology, Dept. of Translational Medicine, Universita del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Hohaus</last_name>
      <phone>+39-0630154180</phone>
      <email>stefan.hohaus@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ALBERTO FABBRI</last_name>
      <phone>+390577585618</phone>
      <email>fabbri7@unisi.it</email>
    </contact>
    <investigator>
      <last_name>ALBERTO FABBRI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>VUMc (Vrije Universiteit Amsterdam)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>LUMC (leidse universitair medisch centrum)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza</name>
      <address>
        <city>Wrocław</city>
        <state>Radeckiego</state>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomasz Wrobel</last_name>
      <phone>+48 533 193 182</phone>
      <email>tomasz_wrobel@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Tomasz Wrobel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpitale Wojewódzkie w Gdyni, Gdyńskie Centrum onkologii</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MCM (Małopolskie Centrum Medyczne)</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny w Legnicy</name>
      <address>
        <city>Legnica</city>
        <zip>59-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jadwiga Holojda</last_name>
      <phone>+48 767211621</phone>
      <email>j.holojda@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jadwiga Holojda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mrek HUS</last_name>
      <phone>+48 81 534 54 68</phone>
      <email>markhus@go2.pl</email>
    </contact>
    <investigator>
      <last_name>Mrek HUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Department St John's Cancer Centre</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krzysztof Giannopoulos</last_name>
      <phone>+48502038268</phone>
      <email>krzysztof.giannopoulos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Giannopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii- Insytut Im. Marii Skłodowskiej-Curie Klinika Nowotworow Ukladu Chlonnego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Military Medical Institute Hematology and Internal Medicine Clinic</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krzysztof Gawronski</last_name>
      <phone>+48 261 817 160</phone>
      <email>kgawronski@wim.mil.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Gawronski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska Curie National Research Institute</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanna Romejko-Jarosinska</last_name>
      <phone>48225462448</phone>
      <email>joanna.romejko-jarosinska@pib-nio.pl</email>
    </contact>
    <investigator>
      <last_name>Joanna Romejko-Jarosinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Provincial Specialist Hospital in Lodz</name>
      <address>
        <city>Łódź</city>
        <zip>62-1010</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut za onkologiju i radiologiju Srbije</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinicko Bolnick Centar Zemun Odeljenje hematologije</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinički centar Srbije Klinika za hematologiju</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kliničko bolnički centar Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinički centar Niš Klinika za hematologiju</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut za onkologiju Vojvodine</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospitla Universitari Germans Trias i Pujol - ICO</name>
      <address>
        <city>Badalona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital University Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad De Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <state>Gloucestershire</state>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>London</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital Cambridge</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Princess Royal University Hospital (PRUH)</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust Oxford Cancer and Haematology Centre, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diffuse large B-cell Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>KPT-330</keyword>
  <keyword>selinexor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

